Cargando…

A Profile of Avelumab Plus Axitinib in the Treatment of Renal Cell Carcinoma

Until recently, the approved first-line treatment for metastatic RCC (mRCC) consisted of tyrosine kinase inhibitors (TKI) targeting the vascular endothelial growth factor receptors (VEGFR) monotherapy. The landscape of first-line treatment has been transformed in the last few years with the advent o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tiako Meyo, Manuela, Chen, Jeanne, Goldwasser, Francois, Hirsch, Laure, Huillard, Olivier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9275425/ https://www.ncbi.nlm.nih.gov/pubmed/35837579 http://dx.doi.org/10.2147/TCRM.S263832

Ejemplares similares

Axitinib in the treatment of renal cell carcinoma: design, development, and place in therapy
por: Bellesoeur, Audrey, et al.
Publicado: (2017)

Avelumab plus axitinib vs. sunitinib for advanced renal-cell carcinoma
por: Zhang, Yue, et al.
Publicado: (2019)

Presurgical avelumab plus axitinib in an immunosenescent octogenarian with renal cell carcinoma invading the vena cava
por: Uematsu, Toshitaka, et al.
Publicado: (2022)

Efficacy of avelumab plus axitinib for advanced renal cell carcinoma as late-line therapy: A case report
por: Uekawa, Ayano, et al.
Publicado: (2022)

A Cost-Effectiveness Analysis: First-Line Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma
por: Lu, Peiyao, et al.
Publicado: (2020)

Avelumab plus axitinib vs sunitinib for advanced renal cell carcinoma: Japanese subgroup analysis from JAVELIN Renal 101
por: Uemura, Motohide, et al.
Publicado: (2020)

Avelumab plus axitinib therapy for renal cell carcinoma in a patient with pulmonary alveolar proteinosis: A case report
por: Shimizu, Nobuaki, et al.
Publicado: (2021)

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101
por: Tomita, Y., et al.
Publicado: (2022)

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma
por: Choueiri, T. K., et al.
Publicado: (2020)

Avelumab Plus Axitinib as First-Line Therapy for Advanced Renal Cell Carcinoma: Long-Term Results from the JAVELIN Renal 100 Phase Ib Trial
por: Larkin, James, et al.
Publicado: (2022)

Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial
por: Choueiri, T.K., et al.
Publicado: (2021)

A case of clear cell renal cell carcinoma with vena cava thrombus responding to presurgical avelumab, and axitinib
por: Suzuki, Issei, et al.
Publicado: (2021)

Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
por: Tomita, Y., et al.
Publicado: (2022)

The Effects of Axitinib plus Tislelizumab in the Treatment of Advanced Renal Cell Carcinoma
por: Wang, Zhixin, et al.
Publicado: (2022)

Cancer treatment during the coronavirus disease 2019 pandemic: Do not postpone but decide wisely
por: Huillard, Olivier, et al.
Publicado: (2020)

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs. Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 Trial
por: Bilen, Mehmet A., et al.
Publicado: (2022)

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma
por: Haanen, J.B.A.G., et al.
Publicado: (2023)

Axitinib plus avelumab in the treatment of recurrent glioblastoma: a stratified, open-label, single-center phase 2 clinical trial (GliAvAx)
por: Awada, Gil, et al.
Publicado: (2020)

Axitinib in Metastatic Renal Cell Carcinoma
por: Mittal, Kriti, et al.
Publicado: (2012)

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer
por: Galffy, G., et al.
Publicado: (2023)

Cost-effectiveness of Pembrolizumab Plus Axitinib Vs Nivolumab Plus Ipilimumab as First-Line Treatment of Advanced Renal Cell Carcinoma in the US
por: Watson, Tina R., et al.
Publicado: (2020)

Critical appraisal of axitinib in the treatment of advanced renal cell carcinoma
por: Ansari, Jawaher, et al.
Publicado: (2013)

Targeted treatments in advanced renal cell carcinoma: focus on axitinib
por: Verzoni, Elena, et al.
Publicado: (2014)

Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives
por: Narayan, Vivek, et al.
Publicado: (2016)

Axitinib for the Management of Metastatic Renal Cell Carcinoma
por: Escudier, Bernard, et al.
Publicado: (2012)

Axitinib: Newly Approved for Renal Cell Carcinoma
por: Tyler, Timothy
Publicado: (2012)

Activity of ipilimumab plus nivolumab in avelumab-refractory Merkel cell carcinoma
por: Glutsch, Valerie, et al.
Publicado: (2021)

Erratum to ‘Efficacy and correlative analyses of avelumab plus axitinib versus sunitinib in sarcomatoid renal cell carcinoma: post hoc analysis of a randomized clinical trial’: [ESMO Open Volume 6, Issue 3, June 2021, 100101]
por: Choueiri, T.K., et al.
Publicado: (2021)

Phase Ib dose-finding study of axitinib plus pembrolizumab in treatment-naïve patients with advanced renal cell carcinoma
por: Atkins, Michael B, et al.
Publicado: (2015)

Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma
por: Gunnarsson, Orvar, et al.
Publicado: (2015)

Response to post-axitinib treatment in patients with metastatic renal cell carcinoma
por: Chittoria, Namita, et al.
Publicado: (2016)

A WIN Consortium phase I study exploring avelumab, palbociclib, and axitinib in advanced non‐small cell lung cancer
por: Solomon, Benjamin, et al.
Publicado: (2022)

Axitinib in sequential therapy in metastatic renal cell carcinoma
por: Kuchar, Agata, et al.
Publicado: (2016)

Axitinib: A Review of its Safety and Efficacy in the Treatment of Adults with Advanced Renal Cell Carcinoma
por: Gross-Goupil, Marine, et al.
Publicado: (2013)

Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study
por: Salimon, Maëva, et al.
Publicado: (2018)

Differential Kinase Activation in Peripheral Blood Mononuclear Cells from Non-Small-Cell Lung Cancer Patients Treated with Nivolumab
por: Noé, Gaëlle, et al.
Publicado: (2019)

Life-threatening Hyperkalemia Associated with Axitinib Treatment in Patients with Recurrent Renal Carcinoma
por: Godo, Shigeo, et al.
Publicado: (2018)

Impaired Retinal Circulation during Axitinib Treatment for Metastatic Renal Cell Carcinoma
por: Kimura, Masashi, et al.
Publicado: (2019)

ATLAS trial of adjuvant axitinib in patients with renal cell carcinoma: subgroup analyses with focus on axitinib dosing and racial groups
por: Quinn, D.I., et al.
Publicado: (2021)

Clinical outcomes of second‐line treatment following first‐line VEGFR‐TKI failure in patients with metastatic renal cell carcinoma: a comparison of axitinib alone and axitinib plus anti‐PD‐1 antibody
por: Huang, Jiwei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_cdcn0tkeafrh8tf4sd44i5l25l